Waddell & Associates LLC Has $999,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Waddell & Associates LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,166 shares of the company’s stock after buying an additional 228 shares during the quarter. Waddell & Associates LLC’s holdings in Johnson & Johnson were worth $999,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Leelyn Smith LLC raised its stake in shares of Johnson & Johnson by 4.1% in the third quarter. Leelyn Smith LLC now owns 17,642 shares of the company’s stock worth $2,859,000 after purchasing an additional 692 shares during the last quarter. Nwam LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at $5,380,000. Meridian Wealth Management LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at $6,897,000. Studio Investment Management LLC boosted its holdings in Johnson & Johnson by 1.5% during the 3rd quarter. Studio Investment Management LLC now owns 29,569 shares of the company’s stock worth $4,792,000 after acquiring an additional 428 shares during the last quarter. Finally, Allen Capital Group LLC raised its holdings in shares of Johnson & Johnson by 6.1% in the third quarter. Allen Capital Group LLC now owns 20,573 shares of the company’s stock valued at $3,334,000 after purchasing an additional 1,190 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $155.14 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The business’s fifty day moving average is $160.21 and its 200 day moving average is $156.21. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market cap of $373.52 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 2.76 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the business earned $2.66 earnings per share. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wells Fargo & Company upped their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.